犬におけるレプトスピラ症治療のグローバル市場展望2022-2028

• 英文タイトル:Canine Leptospirosis Treatment Market, Global Outlook and Forecast 2022-2028

Canine Leptospirosis Treatment Market, Global Outlook and Forecast 2022-2028「犬におけるレプトスピラ症治療のグローバル市場展望2022-2028」(市場規模、市場予測)調査レポートです。• レポートコード:MR2211MG10675
• 出版社/出版日:Market Monitor Global / 2022年11月
• レポート形態:英文、PDF、60ページ
• 納品方法:Eメール(納期:2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥481,000 (USD3,250)▷ お問い合わせ
  Enterprise User¥625,300 (USD4,225)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査資料は次の情報を含め、犬におけるレプトスピラ症治療のグローバル市場規模と予測を記載しています。・犬におけるレプトスピラ症治療のグローバル市場:売上、2017年-2022年、2023年-2028年
・犬におけるレプトスピラ症治療のグローバル市場:販売量、2017年-2022年、2023年-2028年
・世界のトップ5企業、2021年

犬におけるレプトスピラ症治療のグローバル市場規模は2021年に000Mドルと評価され、予測期間中に000%のCAGRで2028年までに000Mドルに達すると予測されています。米国市場は2021年に000Mドルと推定されており、中国は2028年までに000Mドルに達すると予測されています。「経口」セグメントは今後6年間、000%のCAGRで2028年までに000Mドルに成長すると予測されています。

犬におけるレプトスピラ症治療のグローバル主要企業は、Pfizer Inc.、 Baxter International Inc.、 Zoetic Pharmaceuticals Private Limited、 Boehringer Ingelheim International GmbH、 Sun Pharmaceuticals Industries Ltd.、 Aurobindo Pharma、 King Pharmaceuticals、 Hikma Pharmaceuticals PLC、 Almirall LLC.、 Fresenius Kabi USA、 Tolmar Pharmaceuticals, Inc.、 Mayne Pharma Group Limitedなどです。2021年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル(MMG)社は、犬におけるレプトスピラ症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の犬におけるレプトスピラ症治療市場:タイプ別、2017年-2022年、2023年-2028年
世界の犬におけるレプトスピラ症治療市場:タイプ別市場シェア、2021年
・経口、静脈内注射

世界の犬におけるレプトスピラ症治療市場:用途別、2017年-2022年、2023年-2028年
世界の犬におけるレプトスピラ症治療市場:用途別市場シェア、2021年
・動物病院、動物病院、その他

世界の犬におけるレプトスピラ症治療市場:地域・国別、2017年-2022年、2023年-2028年
世界の犬におけるレプトスピラ症治療市場:地域別市場シェア、2021年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における犬におけるレプトスピラ症治療のグローバル売上、2017年-2022年
・主要企業における犬におけるレプトスピラ症治療のグローバル売上シェア、2021年
・主要企業における犬におけるレプトスピラ症治療のグローバル販売量、2017年-2022年
・主要企業における犬におけるレプトスピラ症治療のグローバル販売量シェア、2021年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer Inc.、 Baxter International Inc.、 Zoetic Pharmaceuticals Private Limited、 Boehringer Ingelheim International GmbH、 Sun Pharmaceuticals Industries Ltd.、 Aurobindo Pharma、 King Pharmaceuticals、 Hikma Pharmaceuticals PLC、 Almirall LLC.、 Fresenius Kabi USA、 Tolmar Pharmaceuticals, Inc.、 Mayne Pharma Group Limited

*************************************************************

・調査・分析レポートの概要
犬におけるレプトスピラ症治療市場の定義
市場セグメント
世界の犬におけるレプトスピラ症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の犬におけるレプトスピラ症治療市場規模
世界の犬におけるレプトスピラ症治療市場規模:2021年 VS 2028年
世界の犬におけるレプトスピラ症治療市場規模と予測 2017年-2028年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの犬におけるレプトスピラ症治療の売上
グローバルトップ3およびトップ5企業、2021年売上ベース
グローバル企業の犬におけるレプトスピラ症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:経口、静脈内注射
犬におけるレプトスピラ症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:動物病院、動物病院、その他
犬におけるレプトスピラ症治療の用途別グローバル売上・予測

・地域別市場分析
地域別犬におけるレプトスピラ症治療市場規模 2021年と2028年
地域別犬におけるレプトスピラ症治療売上・予測
北米市場
- アメリカの犬におけるレプトスピラ症治療市場規模2017年-2028年
- カナダの犬におけるレプトスピラ症治療市場規模2017年-2028年
- メキシコの犬におけるレプトスピラ症治療市場規模2017年-2028年
ヨーロッパ市場
- ドイツの犬におけるレプトスピラ症治療市場規模2017年-2028年
- フランスの犬におけるレプトスピラ症治療市場規模2017年-2028年
- イギリスの犬におけるレプトスピラ症治療市場規模2017年-2028年
- イタリアの犬におけるレプトスピラ症治療市場規模2017年-2028年
- ロシアの犬におけるレプトスピラ症治療市場規模2017年-2028年
アジア市場
- 中国の犬におけるレプトスピラ症治療市場規模2017年-2028年
- 日本の犬におけるレプトスピラ症治療市場規模2017年-2028年
- 韓国の犬におけるレプトスピラ症治療市場規模2017年-2028年
- 東南アジアの犬におけるレプトスピラ症治療市場規模2017年-2028年
- インドの犬におけるレプトスピラ症治療市場規模2017年-2028年
南米市場
- ブラジルの犬におけるレプトスピラ症治療市場規模2017年-2028年
- アルゼンチンの犬におけるレプトスピラ症治療市場規模2017年-2028年
中東・アフリカ市場
- トルコの犬におけるレプトスピラ症治療市場規模2017年-2028年
- イスラエルの犬におけるレプトスピラ症治療市場規模2017年-2028年
- サウジアラビアの犬におけるレプトスピラ症治療市場規模2017年-2028年
- UAEの犬におけるレプトスピラ症治療市場規模2017年-2028年

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Pfizer Inc.、 Baxter International Inc.、 Zoetic Pharmaceuticals Private Limited、 Boehringer Ingelheim International GmbH、 Sun Pharmaceuticals Industries Ltd.、 Aurobindo Pharma、 King Pharmaceuticals、 Hikma Pharmaceuticals PLC、 Almirall LLC.、 Fresenius Kabi USA、 Tolmar Pharmaceuticals, Inc.、 Mayne Pharma Group Limited
...

This report contains market size and forecasts of Canine Leptospirosis Treatment in Global, including the following market information:
Global Canine Leptospirosis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Canine Leptospirosis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Canine Leptospirosis Treatment include Pfizer Inc., Baxter International Inc., Zoetic Pharmaceuticals Private Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma, King Pharmaceuticals, Hikma Pharmaceuticals PLC and Almirall LLC., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Canine Leptospirosis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Canine Leptospirosis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Canine Leptospirosis Treatment Market Segment Percentages, by Type, 2021 (%)
Oral
Intravenous Injection
Global Canine Leptospirosis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Canine Leptospirosis Treatment Market Segment Percentages, by Application, 2021 (%)
Veterinary Hospital
Veterinary Clinic
Others
Global Canine Leptospirosis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Canine Leptospirosis Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Canine Leptospirosis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Canine Leptospirosis Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc.
Baxter International Inc.
Zoetic Pharmaceuticals Private Limited
Boehringer Ingelheim International GmbH
Sun Pharmaceuticals Industries Ltd.
Aurobindo Pharma
King Pharmaceuticals
Hikma Pharmaceuticals PLC
Almirall LLC.
Fresenius Kabi USA
Tolmar Pharmaceuticals, Inc.
Mayne Pharma Group Limited

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Canine Leptospirosis Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Canine Leptospirosis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Canine Leptospirosis Treatment Overall Market Size
2.1 Global Canine Leptospirosis Treatment Market Size: 2021 VS 2028
2.2 Global Canine Leptospirosis Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Canine Leptospirosis Treatment Players in Global Market
3.2 Top Global Canine Leptospirosis Treatment Companies Ranked by Revenue
3.3 Global Canine Leptospirosis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Canine Leptospirosis Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Canine Leptospirosis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Canine Leptospirosis Treatment Players in Global Market
3.6.1 List of Global Tier 1 Canine Leptospirosis Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Canine Leptospirosis Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type – Global Canine Leptospirosis Treatment Market Size Markets, 2021 & 2028
4.1.2 Oral
4.1.3 Intravenous Injection
4.2 By Type – Global Canine Leptospirosis Treatment Revenue & Forecasts
4.2.1 By Type – Global Canine Leptospirosis Treatment Revenue, 2017-2022
4.2.2 By Type – Global Canine Leptospirosis Treatment Revenue, 2023-2028
4.2.3 By Type – Global Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Canine Leptospirosis Treatment Market Size, 2021 & 2028
5.1.2 Veterinary Hospital
5.1.3 Veterinary Clinic
5.1.4 Others
5.2 By Application – Global Canine Leptospirosis Treatment Revenue & Forecasts
5.2.1 By Application – Global Canine Leptospirosis Treatment Revenue, 2017-2022
5.2.2 By Application – Global Canine Leptospirosis Treatment Revenue, 2023-2028
5.2.3 By Application – Global Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region – Global Canine Leptospirosis Treatment Market Size, 2021 & 2028
6.2 By Region – Global Canine Leptospirosis Treatment Revenue & Forecasts
6.2.1 By Region – Global Canine Leptospirosis Treatment Revenue, 2017-2022
6.2.2 By Region – Global Canine Leptospirosis Treatment Revenue, 2023-2028
6.2.3 By Region – Global Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country – North America Canine Leptospirosis Treatment Revenue, 2017-2028
6.3.2 US Canine Leptospirosis Treatment Market Size, 2017-2028
6.3.3 Canada Canine Leptospirosis Treatment Market Size, 2017-2028
6.3.4 Mexico Canine Leptospirosis Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country – Europe Canine Leptospirosis Treatment Revenue, 2017-2028
6.4.2 Germany Canine Leptospirosis Treatment Market Size, 2017-2028
6.4.3 France Canine Leptospirosis Treatment Market Size, 2017-2028
6.4.4 U.K. Canine Leptospirosis Treatment Market Size, 2017-2028
6.4.5 Italy Canine Leptospirosis Treatment Market Size, 2017-2028
6.4.6 Russia Canine Leptospirosis Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Canine Leptospirosis Treatment Market Size, 2017-2028
6.4.8 Benelux Canine Leptospirosis Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region – Asia Canine Leptospirosis Treatment Revenue, 2017-2028
6.5.2 China Canine Leptospirosis Treatment Market Size, 2017-2028
6.5.3 Japan Canine Leptospirosis Treatment Market Size, 2017-2028
6.5.4 South Korea Canine Leptospirosis Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Canine Leptospirosis Treatment Market Size, 2017-2028
6.5.6 India Canine Leptospirosis Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country – South America Canine Leptospirosis Treatment Revenue, 2017-2028
6.6.2 Brazil Canine Leptospirosis Treatment Market Size, 2017-2028
6.6.3 Argentina Canine Leptospirosis Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Canine Leptospirosis Treatment Revenue, 2017-2028
6.7.2 Turkey Canine Leptospirosis Treatment Market Size, 2017-2028
6.7.3 Israel Canine Leptospirosis Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Canine Leptospirosis Treatment Market Size, 2017-2028
6.7.5 UAE Canine Leptospirosis Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Corporate Summary
7.1.2 Pfizer Inc. Business Overview
7.1.3 Pfizer Inc. Canine Leptospirosis Treatment Major Product Offerings
7.1.4 Pfizer Inc. Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.1.5 Pfizer Inc. Key News
7.2 Baxter International Inc.
7.2.1 Baxter International Inc. Corporate Summary
7.2.2 Baxter International Inc. Business Overview
7.2.3 Baxter International Inc. Canine Leptospirosis Treatment Major Product Offerings
7.2.4 Baxter International Inc. Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.2.5 Baxter International Inc. Key News
7.3 Zoetic Pharmaceuticals Private Limited
7.3.1 Zoetic Pharmaceuticals Private Limited Corporate Summary
7.3.2 Zoetic Pharmaceuticals Private Limited Business Overview
7.3.3 Zoetic Pharmaceuticals Private Limited Canine Leptospirosis Treatment Major Product Offerings
7.3.4 Zoetic Pharmaceuticals Private Limited Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.3.5 Zoetic Pharmaceuticals Private Limited Key News
7.4 Boehringer Ingelheim International GmbH
7.4.1 Boehringer Ingelheim International GmbH Corporate Summary
7.4.2 Boehringer Ingelheim International GmbH Business Overview
7.4.3 Boehringer Ingelheim International GmbH Canine Leptospirosis Treatment Major Product Offerings
7.4.4 Boehringer Ingelheim International GmbH Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.4.5 Boehringer Ingelheim International GmbH Key News
7.5 Sun Pharmaceuticals Industries Ltd.
7.5.1 Sun Pharmaceuticals Industries Ltd. Corporate Summary
7.5.2 Sun Pharmaceuticals Industries Ltd. Business Overview
7.5.3 Sun Pharmaceuticals Industries Ltd. Canine Leptospirosis Treatment Major Product Offerings
7.5.4 Sun Pharmaceuticals Industries Ltd. Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.5.5 Sun Pharmaceuticals Industries Ltd. Key News
7.6 Aurobindo Pharma
7.6.1 Aurobindo Pharma Corporate Summary
7.6.2 Aurobindo Pharma Business Overview
7.6.3 Aurobindo Pharma Canine Leptospirosis Treatment Major Product Offerings
7.6.4 Aurobindo Pharma Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.6.5 Aurobindo Pharma Key News
7.7 King Pharmaceuticals
7.7.1 King Pharmaceuticals Corporate Summary
7.7.2 King Pharmaceuticals Business Overview
7.7.3 King Pharmaceuticals Canine Leptospirosis Treatment Major Product Offerings
7.7.4 King Pharmaceuticals Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.7.5 King Pharmaceuticals Key News
7.8 Hikma Pharmaceuticals PLC
7.8.1 Hikma Pharmaceuticals PLC Corporate Summary
7.8.2 Hikma Pharmaceuticals PLC Business Overview
7.8.3 Hikma Pharmaceuticals PLC Canine Leptospirosis Treatment Major Product Offerings
7.8.4 Hikma Pharmaceuticals PLC Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.8.5 Hikma Pharmaceuticals PLC Key News
7.9 Almirall LLC.
7.9.1 Almirall LLC. Corporate Summary
7.9.2 Almirall LLC. Business Overview
7.9.3 Almirall LLC. Canine Leptospirosis Treatment Major Product Offerings
7.9.4 Almirall LLC. Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.9.5 Almirall LLC. Key News
7.10 Fresenius Kabi USA
7.10.1 Fresenius Kabi USA Corporate Summary
7.10.2 Fresenius Kabi USA Business Overview
7.10.3 Fresenius Kabi USA Canine Leptospirosis Treatment Major Product Offerings
7.10.4 Fresenius Kabi USA Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.10.5 Fresenius Kabi USA Key News
7.11 Tolmar Pharmaceuticals, Inc.
7.11.1 Tolmar Pharmaceuticals, Inc. Corporate Summary
7.11.2 Tolmar Pharmaceuticals, Inc. Business Overview
7.11.3 Tolmar Pharmaceuticals, Inc. Canine Leptospirosis Treatment Major Product Offerings
7.11.4 Tolmar Pharmaceuticals, Inc. Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.11.5 Tolmar Pharmaceuticals, Inc. Key News
7.12 Mayne Pharma Group Limited
7.12.1 Mayne Pharma Group Limited Corporate Summary
7.12.2 Mayne Pharma Group Limited Business Overview
7.12.3 Mayne Pharma Group Limited Canine Leptospirosis Treatment Major Product Offerings
7.12.4 Mayne Pharma Group Limited Canine Leptospirosis Treatment Revenue in Global Market (2017-2022)
7.12.5 Mayne Pharma Group Limited Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Canine Leptospirosis Treatment Market Opportunities & Trends in Global Market
Table 2. Canine Leptospirosis Treatment Market Drivers in Global Market
Table 3. Canine Leptospirosis Treatment Market Restraints in Global Market
Table 4. Key Players of Canine Leptospirosis Treatment in Global Market
Table 5. Top Canine Leptospirosis Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Canine Leptospirosis Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Canine Leptospirosis Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Canine Leptospirosis Treatment Product Type
Table 9. List of Global Tier 1 Canine Leptospirosis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Canine Leptospirosis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Canine Leptospirosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Canine Leptospirosis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Canine Leptospirosis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Canine Leptospirosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Canine Leptospirosis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Canine Leptospirosis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Canine Leptospirosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Canine Leptospirosis Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Canine Leptospirosis Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Canine Leptospirosis Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Canine Leptospirosis Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Canine Leptospirosis Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Canine Leptospirosis Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Canine Leptospirosis Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Inc. Corporate Summary
Table 31. Pfizer Inc. Canine Leptospirosis Treatment Product Offerings
Table 32. Pfizer Inc. Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Baxter International Inc. Corporate Summary
Table 34. Baxter International Inc. Canine Leptospirosis Treatment Product Offerings
Table 35. Baxter International Inc. Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Zoetic Pharmaceuticals Private Limited Corporate Summary
Table 37. Zoetic Pharmaceuticals Private Limited Canine Leptospirosis Treatment Product Offerings
Table 38. Zoetic Pharmaceuticals Private Limited Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Boehringer Ingelheim International GmbH Corporate Summary
Table 40. Boehringer Ingelheim International GmbH Canine Leptospirosis Treatment Product Offerings
Table 41. Boehringer Ingelheim International GmbH Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Sun Pharmaceuticals Industries Ltd. Corporate Summary
Table 43. Sun Pharmaceuticals Industries Ltd. Canine Leptospirosis Treatment Product Offerings
Table 44. Sun Pharmaceuticals Industries Ltd. Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Aurobindo Pharma Corporate Summary
Table 46. Aurobindo Pharma Canine Leptospirosis Treatment Product Offerings
Table 47. Aurobindo Pharma Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 48. King Pharmaceuticals Corporate Summary
Table 49. King Pharmaceuticals Canine Leptospirosis Treatment Product Offerings
Table 50. King Pharmaceuticals Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Hikma Pharmaceuticals PLC Corporate Summary
Table 52. Hikma Pharmaceuticals PLC Canine Leptospirosis Treatment Product Offerings
Table 53. Hikma Pharmaceuticals PLC Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Almirall LLC. Corporate Summary
Table 55. Almirall LLC. Canine Leptospirosis Treatment Product Offerings
Table 56. Almirall LLC. Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Fresenius Kabi USA Corporate Summary
Table 58. Fresenius Kabi USA Canine Leptospirosis Treatment Product Offerings
Table 59. Fresenius Kabi USA Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 60. Tolmar Pharmaceuticals, Inc. Corporate Summary
Table 61. Tolmar Pharmaceuticals, Inc. Canine Leptospirosis Treatment Product Offerings
Table 62. Tolmar Pharmaceuticals, Inc. Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Mayne Pharma Group Limited Corporate Summary
Table 64. Mayne Pharma Group Limited Canine Leptospirosis Treatment Product Offerings
Table 65. Mayne Pharma Group Limited Canine Leptospirosis Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Canine Leptospirosis Treatment Segment by Type in 2021
Figure 2. Canine Leptospirosis Treatment Segment by Application in 2021
Figure 3. Global Canine Leptospirosis Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Canine Leptospirosis Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Canine Leptospirosis Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Canine Leptospirosis Treatment Revenue in 2021
Figure 8. By Type - Global Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
Figure 12. US Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
Figure 24. China Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Canine Leptospirosis Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Canine Leptospirosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Inc. Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Baxter International Inc. Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Zoetic Pharmaceuticals Private Limited Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Boehringer Ingelheim International GmbH Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Sun Pharmaceuticals Industries Ltd. Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Aurobindo Pharma Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. King Pharmaceuticals Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Hikma Pharmaceuticals PLC Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Almirall LLC. Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Fresenius Kabi USA Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Tolmar Pharmaceuticals, Inc. Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Mayne Pharma Group Limited Canine Leptospirosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)




• 英文レポート名:Canine Leptospirosis Treatment Market, Global Outlook and Forecast 2022-2028
• 日本語訳:犬におけるレプトスピラ症治療のグローバル市場展望2022-2028
• レポートコード:MR2211MG10675お問い合わせ(見積依頼・ご注文・質問)